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Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with chronic kidney disease 
(CKD) patients. Serum albumin, a negative acute-phase reactant and marker for underlying inflammation and/or 
malnutrition, is an independent predictor of CVD and mortality in CKD VI patients. Such an association in pa-
tients with less severe CKD is not well established. 
We conducted a cross sectional study of all CKD II - IV patients attending the nephrology clinic (N=376; mean 
age: 57±17 years; GFR: 47±20 mL/min/1.73m2; females 48%; blacks 15%; diabetics 27%; hypertensive 79%). 
Laboratory and clinical data including risk factors and evidence of CVD were obtained at the point of the most 
recent visit. The association between risk factors and CVD was evaluated by logistic regression. In the simple 
logistic regression model, age (p<0.0001), sex (P= 0.02), hypertension (P<0.0001), diabetes (P<.0001), dyslipidemia 
(p=.01), and serum albumin (p<.0001) were found to be statistically significant. Serum albumin was found to be 
an independent predictor (p=0.04) of CVD by multiple logistic regression analysis using the above risk factor 
variables. 
In conclusion: a) hypoalbuminaemia is an independent predictor of CVD in early CKD stages; b) hypoalbu-
minaemia may be used to identify the population at higher risk for CVD. 
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INTRODUCTION 
400,000 Americans have ESRD and over 300,000 
of these patients are on maintenance dialysis (1). CVD 
is the leading cause of morbidity and mortality in these 
patients accounting for more than 40% of hospitaliza-
tions and almost 50% of deaths (1, 2). This death rate 
attributed to CVD is 10-20 times that in the general 
population, stratified for age, race and gender (3).  
An estimated 8 million patients have chronic 
kidney disease of at least stage III (as defined by an 
estimated glomerular filtration rate [GFR] of less than 
60 ml per minute per 1.73 m2 of body surface area) (4). 
These patients are not on dialysis. However, the 
prevalence of CVD in these patients has been shown to 
be significantly higher than the general population (5, 
6).  
The high burden of CVD in these patients can not 
be explained just by the high prevalence of traditional 
risk factors like hypertension (HTN), diabetes (DM), 
Dyslipidemia (DLP) and advanced age. Of late, novel 
risk factors like malnutrition and inflammatory state 
have been implicated in maintenance dialysis patients 
(CKD stage VI). This association is not well established 
in patients with less severe CKD. Here we evaluated 
association between serum albumin, a negative 
acute-phase reactant and marker of inflammation 
and/or malnutrition and CVD in patients with CKD 
stages II to IV. 
METHODS 
STUDY DESIGN 
This is a cross sectional study of all CKD stage 
II-IV (n= 376) patients attending nephrology clinic of a 
community hospital. Excluded from initial sample of 
583 patients were those with CKD stage I, V and those 
with missing albumin values or CVD data. Patients 
with a previous history of dialysis and/or renal trans-
plant were also excluded. 
DATA COLLECTION 
Data of age, sex, race, DM, HTN, serum chemis-
tries and CVD were collected from office charts and 
from the most recent visit. All names and identifiers Int. J. Med. Sci. 2008, 5 
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were removed before any analysis of data was per-
formed. Serum chemistries included blood urea ni-
trogen (BUN), serum creatinine, serum albumin, elec-
trolytes, calcium (Ca), phosphorus (PO4), uric acid, 
lipids and hemoglobin. CVD included angina pectoris, 
myocardial infarction (MI), coronary artery disease 
(CAD), left ventricular hypertrophy (LVH) and heart 
failure (HF) as per history. 
RENAL FUNCTI0N 
We used the abbreviated Modification of diet in 
Renal Disease (MDRD) equation to estimate the GFR 
(7, 8). Creatinine value on last visit was used to calcu-
late MDRD eGFR. The formula is as below: 
186 x (Creat / 88.4)-1.154 x (Age)-0.203 x (0.742 if fe-
male) x (1.210 if black) 
OUTCOMES AND COVARIATES 
Outcomes were measured in form of prevalence 
of CVD as defined above. Potential confounders se-
lected based on prior studies and clinical relevance, 
including age, sex, HTN, DM and DLP were used in 
final model. 
STATISTICAL ANALYSIS 
Results were expressed as mean ± SD for con-
tinuous variables, and as percentages for categorical 
data. The association between potential risk factors 
and CVD was evaluated by logistic regression model. 
Simple logistic regression models were used to evalu-
ate associations of traditional and novel risk factors for 
CVD. To evaluate the independent effect of serum al-
bumin on CVD, a multiple logistic regression model 
was used. All variables known to be associated with 
CVD involving all traditional risk factors like sex, age, 
DM, HTN, DLP were put in final multiple logistic re-
gression model to remove confounding effects. Results 
were reported as p values and Odds Ratios with 95% 
confidence intervals. All analyses were conducted with 
the use of STATVIEW software. 
RESULTS 
The patients included 52% male and 48% female, 
85% white and 15% black and mean age was 57 years. 
The majority of patients (79%) had HTN and 27% had 
DM. CVD was prevalent in 35% of patients. A total of 
62% were on angiotensin converting enzyme inhibitors 
(ACE-i), 30% on beta blockers and 53% on statins (Ta-
ble 1). Laboratory data is shown in Table 2. All vari-
ables evaluated using simple logistic regression were 
significant except serum cholesterol (Table 3). The ef-
fects of BUN, serum creatinine, calcium, phosphorus, 
uric acid, and hemoglobin values on CVD were ac-
counted by the GFR status. Multivariate analysis 
showed that GFR, serum albumin concentration, age, 
male sex and presence of DM were the independent 
predictors of CVD in the earlier stages of CKD (Table 
4).  
Table 1: Characteristics of patients with CKD stage II to IV 
excluding patient with history of renal transplant or maintenance 
dialysis. 
Variable Value 
Age (years)  57±17 
Sex 48%  Female,   
52% Male 




Cardiovascular disease  35% 
ACEi/ ARB  62% 
Beta blockers  40% 
Statins 53% 
Table 2: Laboratory data of the study patients with CKD stage 
II to IV including serum chemistries. 
Parameter  Mean ± SD 
MDRD GFR (mL/min/1.73m2):  47 ± 20 
BUN (mg/dL):  28 ± 16 
S. Creatinine (mg/dL):  1.6 ± 0.7 
S. Calcium (mg/dL):  9.4 ± 0.5 
S. Phosphorus (mg/dL):  3.6 ± 0.6 
S. Albumin (g/dL):  4.1 ± 0.5 
S. Uric Acid (mg/dL):  7.0 ± 2.3 
S. Cholesterol (mg/dL):  188 ± 43 
S. Triglycerides (mg/dL):  169 ± 136 
S. hemoglobin (g/dL):  13.2±1.8  
Table 3: Univariate Logistic Regression Analysis evaluating 
association of risk factors with CVD. 
Variable  Exp (coef.)  P Value 
Age: 1.065  0.0100 
Sex (M):  1.689  0.0170 
Race (W):  0.489  0.0140 
HTN: 5.422  0.0001 
DM: 3.849  0.0001 
S. Phosphorus  1.609  0.0063 
S. Uric Acid:  1.287  0.0001 
GFR: 0.952  0.0001 
S. Hemoglobin:  0.740  0.0001 
S. Calcium  0.539  0.0041 
S. Albumin:  0.376  0.0001 
S. Cholesterol:  0.997  0.3377 
Table 4: Multivariate Logistic Regression Analysis evaluating 
independent effects of risk factors with CVD.   
Variable  P Value  Exp (Coef.)  OR (95% CI) 
Age: 0.0001  1.043  (1.023-1.063) 
Sex (M):  0.0280  1.788  (1.065-3.002) 
HTN: 0.0714  2.127 (0.936-4.833) 
DM: 0.0012  2.472  (1.430-4.273) 
GFR: 0.0004  0.976  (0.961-0.992) 
S. Albumin:  0.0365  0.554  (0.391-0.962) 
DISCUSSION 
The majority of patients with CKD have severe 
manifestations of CVD by the time they need mainte-Int. J. Med. Sci. 2008, 5 
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nance dialysis. This suggests that the damage to the 
cardiovascular system starts quite early in the time 
course of progressive chronic kidney disease. Indeed 
over the last few years, it has been well recognized that 
CKD patients in the predialysis stage are at increased 
risk of CVD and its complications. This has led to a 
rapidly growing interest in the relation between kid-
ney disease and the risk of CVD and is the focus of 
several recent studies. These studies have shown that 
the association of CKD to CVD is independent of any 
traditional risk factors (9-12). The National Kidney 
Foundation, American Heart Association and the 
Seventh Joint National Committee on Prevention, De-
tection, Evaluation & Treatment of High Blood Pres-
sure have classified the presence of CKD as a cardio-
vascular risk factor (9, 13, 14). These findings led to the 
evaluation of novel cardiovascular risk factors like 
chronic inflammation and malnutrition as predictors 
of the CVD in chronic kidney disease. This multifacto-
rial disease introduces new challenges in predicting 
and treating patients early in course of CKD to posi-
tively alter patient outcome. 
There is definitely a high prevalence of traditional 
risk factors like HTN, DM and DLP in chronic kidney 
disease patients (15-20), but this alone cannot explain 
the existing high burden of CVD in this population 
(21-24). There appears to be a close link between CVD, 
malnutrion and inflammation in ESRD patients (25, 
26). Hypoalbuminemia, a marker of malnutrition and 
underlying inflammation has come up as a powerful 
predictor of mortality in patients with ESRD (27-30) 
and also a significant predictor for the occurrence of de 
novo vascular events in this population (27). In a re-
cent study C-reactive protein and low albumin has 
been shown to be the predictor of morbidity and mor-
tality in CKD 3-5 patients in Spain (31). Our study ex-
tends this finding to patients with more preserved 
renal function in American population. 
Our hypothesis that serum albumin is a signifi-
cant risk factor for cardiovascular disease in CKD pa-
tients is highlighted by our results on 376 patients with 
CKD II to IV in whom low serum albumin was sig-
nificantly associated with CVD irrespective of tradi-
tional risk factors like age, sex, HTN, DM and DLP in 
multivariate analysis.  
Beddhu et al (32) showed association between 
serum albumin level and CVD in chronic hemodialysis 
patients. An association between serum albumin and 
cardiovascular mortality has been reported by several 
studies. Owen et al (33) demonstrated that hypoalbu-
minemia was a strong predictor of mortality in dialysis 
patients. Kalantar-Zadeh et al (34) also showed higher 
mortality in dialysis patients with lower albumin. 
Many recent studies showed serial measurement of 
serum albumin can even better predict chronic in-
flammation and clinical events (35-37). Looking at the 
results of all these studies it is clear that hypoalbu-
minemia is adversely associated with CVD in ESRD. 
Stenvinkel et al. (38) were first to demonstrate that 
patients in predialysis chronic renal failure with ca-
rotid plaque has lower serum albumin level. Nobuhiko 
et al demonstrated that even in predialytic phase of 
chronic renal failure, hypoalbuminemia is an excellent 
reflection of CVD (39). Our study concludes that this is 
true even in patients with less severe kidney dysfunc-
tion. So serum albumin can be a helpful predictor of 
CVD at early stage of CKD and this patient population 
needs focused attention because early detection and 
intervention can provide better outcome. 
Available data suggests interrelationship be-
tween hypoalbuminemia, inflammation, malnutrition 
and atherosclerosis in patients with kidney failure (38, 
40). In some studies the relation between hypoalbu-
minemia and CVD is the reflection of inflammation 
induced malnutrition. The underlying mechanism be-
hind this includes appetite suppression and increased 
catabolism by inflammatory cytokines (38). Cai and 
colleagues have implied serum albumin as potential 
scavenger of free radicals. Decrease in serum albumin 
level would lead to decrease antioxidant capacity and 
favor the noxious effects of oxidative stress on a vari-
ety of tissues, including the arterial vessel wall (41). 
These data suggest that hypoalbuminaemia can be 
more appropriately viewed as a composite marker 
which reflects malnutrition as well as increased acute 
phase inflammation, considering that albumin is also a 
negative acute phase reactant (38, 42-45).  
Our study has several limitations. This was a 
retrospective chart review. Patients were not followed 
over time, so causal relationships cannot be estab-
l i s h e d .  W e  h a v e  n o t  u s e d  s e r u m  a l b u m i n  a s  a  t i m e  
dependent covariate which may have led to an even 
more reliable prediction of CVD. In addition, many of 
our patients were on medications that have protective 
effects on cardiovascular disease. Another important 
limitation is the lack of consistent measurements of 
other inflammatory markers such as CRP, whose im-
portance as a predictor of CVD has been shown by 
others (46). Hypoalbuminemia is a non specific marker 
of a micro inflammatory state, and is seen in other 
diseases such as systemic lupus, rheumatoid arthritis, 
other connective tissue diseases, liver disease, malnu-
trition from other causes, and does not just represent 
cardiovascular disease. In addition, data on food in-
take, basal energy expenditure (BEE), and total daily 
energy expenditure (TEE) were not available for 
analysis that may have provided a better understand-
ing of nutritional status in these patients. Int. J. Med. Sci. 2008, 5 
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Our study concludes that hypoalbuminemia is a 
strong risk factor for CVD, probably in context of the 
complex syndrome of malnutrition, inflammation and 
oxidative stress in patients with CKD. In order to re-
duce cardiovascular mortality, nutritional, 
anti-inflammatory and antioxidant intervention will 
need to be assessed in more randomized control trials. 
Statins and ACE inhibitors have been shown to have 
anti-inflammatory effects (47, 48). Recent studies have 
shown beneficial effects of statins on CVD outcome in 
CKD patients (49-51). But it is unclear whether the 
benefit is due to lipid lowering effect, an anti inflam-
matory effect or both.  
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